AstraZeneca's 4th-qtr 2006 profits jump 17%, in line with expectations
Anglo-Swedish drug major AstraZeneca posted a strong set of financial results for the fourth quarter and full year 2006 - in line with analysts' consensus expectations - but, even though it forecast ongoing strong growth, said it would be cutting 3,000 jobs.
Sales for the quarter rose 14% (+11% at constant exchange rates) to $7.15 billion, and were up 11% to $26.47 billion for the year. Pretax profit was up 25% at $2.10 billion, or $0.93 a share, for the three months and 28% higher at $8.54 billion, or $3.86 a share, for the year.
For the first time, AstraZeneca presented a forward earnings guidance, saying that it expects sales growth in the high single digits and set a target for earnings per share of $3.80-$4.05.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze